Action FBLG FIBROBIOLOGICS, INC.
Ajouter à une liste
Pour utiliser cette fonction vous devez être client ou membre
ConnexionInscription

Communiqués FibroBiologics, Inc.

Actions

FBLG

US31573L1052

Marché Fermé - Nasdaq
Autres places de cotation
 22:00:00 28/06/2024 		Varia. 5j. Varia. 1 janv.
4,99 USD +7,08% Graphique intraday de FibroBiologics, Inc. +5,27% 0,00%
25/06 Fibrobiologics annonce une preuve de concept préliminaire pour une nouvelle technologie d'organoïde de thymus artificiel CI
13/06 FibroBiologics rejoindra l'indice Russell 2000 en juillet MT

Communiqués

Recherche
Voir les résultats
Débloquez toutes les actualités : Soyez le premier informé et réagissez avant les marchés !
Inscription 100% Gratuite
FibroBiologics Announces Preliminary Proof of Concept for Novel Artificial Thymus Organoid Technology
GL
FibroBiologics Set to Join Russell 2000® Index
GL
FibroBiologics to Present at Extracellular Matrix Pharmacology Congress 2024
GL
FibroBiologics Announces 2024 Annual Meeting of Stockholders
GL
FibroBiologics Files 2024 First Quarter Report
GL
FibroBiologics to Present at the BIO International Convention 2024
GL
FibroBiologics Plans to Collaborate with Charles River to Manufacture Fibroblast-based Spheroids
GL
FibroBiologics Granted Patent for Regeneration of Cartilage-Type Cells by the Australian Patent Office
GL
FibroBiologics Presents Data from Dermal Fibroblast Spheroid-based Treatment of Chronic Wounds in a Diabetes Mouse Model at Advanced Wound Care Summit USA
GL
FibroBiologics Files Patent Application Covering Fibroblast-based Technology for the Potential Treatment of Lupus
GL
FibroBiologics Announces Preliminary Proof of Concept for Fibroblast-based Diabetes Treatment
PR
FibroBiologics to Present at Advanced Wound Care Summit USA
PR
FibroBiologics Appoints Ruben A. Garcia as General Counsel
PR
FibroBiologics Files 2023 Form 10-K Annual Report
PR
FibroBiologics to Present Preclinical and Clinical Data at the 2024 Americas Committee for Treatment and Research in Multiple Sclerosis Forum
AQ
FibroBiologics to Present Preclinical and Clinical Data at the 2024 Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum
PR
FibroBiologics Presents Preclinical Data at the 2024 Keystone Symposia for Systemic Autoimmune and Autoinflammatory Diseases
PR
FibroBiologics Announces Three United States Patents for Fibroblast Technology
PR
FibroBiologics Announces Three Japanese Patents on Fibroblast Technology
PR
Aucun résultat pour cette recherche
Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Filtres

Rechercher

Date de publication

Depuis le

Jusqu'au

  1. Bourse
  2. Actions
  3. Action FBLG
  4. Actualités FibroBiologics, Inc.
  5. Communiqués